JSR Life Sciences Expands Its European Gene-to-GMP Biologics Manufacturing Facilities for Selexis and KBI Biopharma in Geneva, Switzerland
20.10.2020 14:00:00 EEST | Business Wire | Press release
JSR Life Sciences, LLC today announced that it is increasing its European footprint with a newly expanded, state-of-the-art facility that will co-locate primary European operations for its affiliate companies KBI Biopharma and Selexis SA. The two companies combined will occupy 8,700 square meters in the Stellar 32 campus within Geneva’s ZIPLO (Industrial Zone Plan-les-Ouates). KBI Biopharma’s expanded facility will enable the Company to offer clinical cGMP biologics bulk drug substance manufacturing for European clients. Selexis’ new workspaces will allow the Company to meet the increasing demand for its highly specialized mammalian cell line development technologies and services. Together, the companies anticipate creating more than 250 new highly technical jobs in the new facilities.
JSR Life Sciences invested in the co-located operations to help meet the needs of its European client base. This arrangement will facilitate additional options for clients to leverage efficiencies for integrating Selexis’ SUREtechnology TM protein expression platform with KBI’s advanced process and analytical development tools.
“JSR Life Sciences is proud to have best-in-class companies focused on translating customers’ ideas into novel biologics that are improving patients’ lives worldwide,” said Tim Lowery, President of JSR Life Sciences. “This strategic investment in our European operations creates new options by linking the core strengths of our affiliates, increases efficiencies, and ultimately accelerates our customers’ ability to bring innovative life science products into the marketplace. In addition, KBI and Selexis will benefit from the extensive biopharma industrial base, advanced technical resources, and specialized education offerings in this region.”
KBI Biopharma’s new 5,600-square-meter biologic bulk drug substance manufacturing facility is scheduled to be operational by mid-2022 and will create more than 200 technical positions in development, operations, and quality assurance. From this facility, KBI will supply customers with cGMP bulk drug substance to meet their clinical trial requirements. The expanded capabilities include two 2,000L single-use cGMP manufacturing trains with process development and analytical testing labs on site. cGMP quality control testing for release and in-process testing will be performed on-site in the new Geneva facility, while cGMP testing of drug substance and drug product stability will remain at the KBI Biopharma BVBA laboratories in Leuven, Belgium.
Selexis’ Geneva footprint will increase by 200% and is scheduled to be operational by mid-2021. The new space will include laboratory, office, health/wellness, and employee common spaces. Throughout the expansion, Selexis has maintained its commitment to Corporate Social Responsibility (CSR) through investing in a Minergie-certified building (a Swiss building standard aimed at construction with above-average demands on quality, comfort, and energy) with an energy balance 20% better than Swiss recommendations for energy resource and conservation1. Floorplans support the unique technical needs of Selexis cell line workflows, including department-wide segregation and state-of-the-art monitoring systems. In addition to new standard cell line development suites, the new facility will also include two separate cell culture suites to accommodate quarantined client-specific cell lines or client-dedicated cell line spaces.
“This expansion is a cornerstone of our European growth strategy, which builds on Selexis’ innovative cell line technologies and KBI’s strong expertise in biologics manufacturing to meet the needs of our clients’ clinical trial requirements. The new facility allows us to increase engagement with a broader client base with whom we can partner more effectively due to our local presence,” said Dirk Lange, President and CEO of KBI Biopharma and CEO of Selexis SA. “As science progresses, research and treatments become increasingly complex and sophisticated, and we are fully prepared to keep pace with our clients’ needs by providing the latest life science discovery and development technology. Furthermore, by co-locating these operations, the synergies for rapid cell line and process development and introduction to manufacturing will be tremendous, which we see as a true advantage for our client base.”
The Stellar 32 facility remains in the center of highly diversified industrial companies in Geneva. It provides easy access for clients and employees, located close to the A1 Motorway, Geneva Airport, and public transportation including buses, trams, and multiple railways. The location will also provide convenient access to a three-star hotel as well as a restaurant and fitness center.
About JSR Life Sciences, LLC
JSR Life Sciences, LLC is committed to the advancement of human health worldwide as a strategic partner to companies that discover, develop, and deliver products to treat disease and improve the quality of life for patients. Based in Sunnyvale, California, JSR Life Sciences operates a network of manufacturing facilities, R&D labs and sales offices. The JSR Life Sciences family of companies includes Crown Bioscience, KBI Biopharma, Inc., Medical & Biological Laboratories Co., LTD., Selexis SA and other affiliates throughout Europe and the Asia-Pacific region.
About KBI Biopharma, Inc.
KBI Biopharma is an award-winning biopharmaceutical contract services organization providing fully integrated, accelerated drug development and biomanufacturing services to pharmaceutical and biotechnology companies globally. With each of our 300+ client partners, we have worked closely to personalize and rapidly accelerate their drug development programs. Built upon a foundation of world-class analytical capabilities, we deliver efficient process development and clinical and commercial cGMP manufacturing services for mammalian, microbial, and cell therapy programs. We have locations in Durham and Research Triangle Park (NC), Boulder and Louisville (CO), The Woodlands (TX), Geneva, Switzerland, and Leuven, Belgium. More information is available at www.kbibiopharma.com.
About Selexis SA
Selexis SA, a JSR Life Sciences Company, is the global leader in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop, and commercialize innovative medicines and vaccines. Our global partners are utilizing Selexis technologies to advance more than 130 drug products in clinical development and the manufacture of eight commercial products. As part of a comprehensive drug development process, the Company’s technologies shorten development timelines and reduce manufacturing risks. More information is available at www.selexis.com.
1 The “Model Regulations of the Cantons in the Energy Sector” (MuKEn) is the “overall package” of energy law model regulations in the building sector that the cantons have jointly developed based on their implementation experience.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201020005340/en/
Contact information
Media Inquiries
Mike Beyer
Sam Brown Inc.
+1 312-961-2502
mikebeyer@sambrown.com
Company Inquiries
Missy Bindseil
JSR North America Holdings, Inc.
JSR Life Sciences, LLC
+1 830-237-9527
mbindseil@jsr-nahq.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Great Britain Leads Europe’s FMCG Inflation as NIQ Launches New Inflation Barometer6.8.2026 10:00:00 EEST | Press release
NIQ (NYSE: NIQ) today launches its new EU5 FMCG Inflation Barometer - a monthly tracker across five Western Europe markets – France, Great Britain, Germany, Italy and Spain – designed to help retailers, manufacturers and the media understand how inflation is evolving across Europe’s largest grocery markets and how shoppers are responding. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806579111/en/ EU5 CPG Inflation slows to +1.1% The first edition of the Barometer reveals that while inflation across Europe’s FMCG sector remains relatively contained overall, significant differences persist between countries. Key findings include: Great Britain recorded the highest FMCG inflation across the EU5 at +2.3%1, above the European average of +1.1%. France and Italy reported the lowest inflation at -0.4% and +0.6% retrospectively, highlighting the uneven inflationary landscape across Europe's major economies. The monthly Barometer
NTT DOCOMO BUSINESS and Chile’s State-owned Copper Company CODELCO Launch a Study and Proof of Concept Aimed at Improving the Efficiency of Remote Copper Mine Operations Using IOWN ® APN6.8.2026 07:30:00 EEST | Press release
NTT DOCOMO BUSINESS, Inc. (formerly NTT Communications Corporation) has launched a study and proof of concept jointly with Corporación Nacional del Cobre de Chile (CODELCO) to progress remote operations at CODELCO’s copper mines using an IOWN® All-Photonics Network (APN).1 This initiative is part of a research project commissioned by Japan’s Ministry of Internal Affairs and Communications.2 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806845222/en/ Conceptual Diagram of the Demonstration To address operational challenges faced by CODELCO’s copper mines, the initiative will connect a copper mine and a remote operations center—approximately 1,500 km apart—via an IOWN APN. It will assess the feasibility of remotely operating heavy machinery using high-capacity, low-latency communication links, enhancing monitoring operations through high-definition video, and implementing a remote operations model. 1. Background Chile is o
FPT Named an OpenAI Select Partner6.8.2026 03:00:00 EEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 01:10:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of ORZEYFUL marks a new chapter for the narcolepsy type 1 community, as we introduce an entirely new class of medicine that will potentially redefine how this disease is managed and howpeople feel on treatment,” said Julie Kim, president and chief executive officer of Takeda. “We are proud to have discovered and developed this orexin treatment innovation and will bring it to adults living with NT1 as quickly as possible.” NT1 is a rare, chronic neurological disease d
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 23:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom